CN112334451A - 作为激酶抑制剂的杂环化合物 - Google Patents

作为激酶抑制剂的杂环化合物 Download PDF

Info

Publication number
CN112334451A
CN112334451A CN201980025159.XA CN201980025159A CN112334451A CN 112334451 A CN112334451 A CN 112334451A CN 201980025159 A CN201980025159 A CN 201980025159A CN 112334451 A CN112334451 A CN 112334451A
Authority
CN
China
Prior art keywords
formula
compound
alkylene
salt
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025159.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·M·范
S·查克拉瓦提
J·堪卡纳拉
B·普贾拉
A·谢特
B·巴哈特
A·K·阿加瓦尔
S·索尼
J·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelson Biological Co ltd
Original Assignee
Novelson Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelson Biological Co ltd filed Critical Novelson Biological Co ltd
Publication of CN112334451A publication Critical patent/CN112334451A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980025159.XA 2018-02-15 2019-02-15 作为激酶抑制剂的杂环化合物 Pending CN112334451A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862631437P 2018-02-15 2018-02-15
US62/631,437 2018-02-15
PCT/US2019/018244 WO2019161224A1 (en) 2018-02-15 2019-02-15 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN112334451A true CN112334451A (zh) 2021-02-05

Family

ID=67542098

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025159.XA Pending CN112334451A (zh) 2018-02-15 2019-02-15 作为激酶抑制剂的杂环化合物

Country Status (13)

Country Link
US (2) US11174252B2 (enExample)
EP (1) EP3752491A4 (enExample)
JP (1) JP2021514359A (enExample)
KR (1) KR20200131246A (enExample)
CN (1) CN112334451A (enExample)
AU (1) AU2019220746A1 (enExample)
BR (1) BR112020015431A2 (enExample)
CA (1) CA3089592A1 (enExample)
IL (1) IL276509A (enExample)
MA (1) MA51846A (enExample)
MX (1) MX2020008559A (enExample)
SG (1) SG11202007754UA (enExample)
WO (1) WO2019161224A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264920A (zh) * 2021-05-10 2021-08-17 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用
CN114502536A (zh) * 2019-08-14 2022-05-13 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN116947840A (zh) * 2022-04-27 2023-10-27 润佳（苏州）医药科技有限公司 一种cdk降解剂及其用途
WO2024051702A1 (zh) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126731A1 (en) * 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US20220281859A1 (en) * 2019-08-14 2022-09-08 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
CN113244386A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
IL296025A (en) * 2020-03-02 2022-10-01 Sironax Ltd Proptosis inhibitors - diarylamine para-acetamides
WO2022078309A1 (zh) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
US20220259195A1 (en) * 2021-02-03 2022-08-18 Nuvation Bio Inc. Crystalline forms of a cyclin-dependent kinase inhibitor
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
WO2022236253A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236256A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236255A2 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022236257A1 (en) * 2021-05-03 2022-11-10 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2022261643A1 (en) * 2021-06-09 2022-12-15 Nuvation Bio Inc. Treating cancers with a cyclin-dependent kinase inhibitor
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS
AU2023263197A1 (en) * 2022-04-29 2024-11-14 Beigene , Ltd. Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors
KR20250044316A (ko) * 2022-07-29 2025-03-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
EP4618755A1 (en) * 2022-11-15 2025-09-24 Larkspur Biosciences, Inc. Inhibitors and degraders of pip4k protein
CN121443601A (zh) * 2023-07-03 2026-01-30 英矽智能科技知识产权有限公司 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法
WO2025247364A1 (zh) * 2024-05-30 2025-12-04 山东先声生物制药有限公司 杂环化合物作为cdk抑制剂及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087922A1 (en) * 2001-03-29 2003-05-08 Bethiel Randy S. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20040097504A1 (en) * 2002-11-04 2004-05-20 Bethiel Randy S. Compositions useful as inhibitors of jak and other protein kinases
CN102918043A (zh) * 2010-02-19 2013-02-06 诺瓦提斯公司 作为cdk4/6抑制剂的吡咯并嘧啶化合物
US20170182043A1 (en) * 2014-09-12 2017-06-29 G1 Therapeutics, Inc. Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
WO2017177837A1 (zh) * 2016-04-11 2017-10-19 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2007024949A2 (en) 2005-08-25 2007-03-01 Schering Corporation Alpha2c adrenoreceptor agonists
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2580213A4 (en) 2010-06-09 2013-12-25 Afraxis Holdings Inc 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US20130252967A1 (en) 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
ES2525866T3 (es) 2010-08-05 2014-12-30 Temple University - Of The Commonwealth System Of Higher Education 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2013175415A1 (en) 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
DK3149008T3 (en) 2014-05-28 2019-04-01 Shanghai Fochon Pharmaceutical Co Ltd Specific protein kinase inhibitors
WO2016015605A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN105294682B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN111333627B (zh) 2015-03-11 2024-09-13 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN108699055B (zh) 2015-12-13 2020-10-23 杭州英创医药科技有限公司 用作抗癌药物的杂环化合物
CN108779117B (zh) 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
WO2017133701A1 (en) 2016-02-06 2017-08-10 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN107286134B (zh) 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
PL3442947T3 (pl) 2016-04-15 2023-10-02 Epizyme, Inc. Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
EP3445765A4 (en) 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
KR102374033B1 (ko) 2016-05-07 2022-03-14 상하이 포천 파마슈티컬 씨오 엘티디 특정 단백질 키나제 억제제
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005865A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
EP3505519B1 (en) 2016-11-11 2022-01-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
WO2018113771A1 (en) 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses theirof
CN107382974B (zh) 2017-06-08 2020-06-05 扬州市三药制药有限公司 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
CN111989099A (zh) 2018-01-29 2020-11-24 贝塔制药有限公司 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12312346B2 (en) 2018-06-27 2025-05-27 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
AU2019309909A1 (en) 2018-07-23 2021-02-04 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
MX2021000895A (es) 2018-07-27 2021-08-24 California Inst Of Techn Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.
CN110835334B (zh) 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113166105B (zh) 2018-11-30 2024-11-08 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087922A1 (en) * 2001-03-29 2003-05-08 Bethiel Randy S. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20040097504A1 (en) * 2002-11-04 2004-05-20 Bethiel Randy S. Compositions useful as inhibitors of jak and other protein kinases
CN102918043A (zh) * 2010-02-19 2013-02-06 诺瓦提斯公司 作为cdk4/6抑制剂的吡咯并嘧啶化合物
US20170182043A1 (en) * 2014-09-12 2017-06-29 G1 Therapeutics, Inc. Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
WO2017177837A1 (zh) * 2016-04-11 2017-10-19 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502536A (zh) * 2019-08-14 2022-05-13 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN113264920A (zh) * 2021-05-10 2021-08-17 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用
CN116947840A (zh) * 2022-04-27 2023-10-27 润佳（苏州）医药科技有限公司 一种cdk降解剂及其用途
WO2024051702A1 (zh) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Also Published As

Publication number Publication date
US20190248774A1 (en) 2019-08-15
US20230062022A1 (en) 2023-03-02
CA3089592A1 (en) 2019-08-22
MX2020008559A (es) 2021-01-08
SG11202007754UA (en) 2020-09-29
EP3752491A4 (en) 2021-12-01
KR20200131246A (ko) 2020-11-23
WO2019161224A1 (en) 2019-08-22
EP3752491A1 (en) 2020-12-23
IL276509A (en) 2020-09-30
MA51846A (fr) 2021-04-21
JP2021514359A (ja) 2021-06-10
US11174252B2 (en) 2021-11-16
AU2019220746A1 (en) 2020-08-27
BR112020015431A2 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
CN112334451A (zh) 作为激酶抑制剂的杂环化合物
KR102578325B1 (ko) Usp30 억제제로서의 1-시아노-피롤리딘 화합물
AU2010254806B2 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP5241834B2 (ja) プロテインキナーゼ阻害剤としての複素環アミド化合物
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
HK1231475A1 (zh) Tank-结合激酶抑制剂化合物
CN114340634A (zh) 作为激酶抑制剂的杂环化合物
CN112279852A (zh) 三唑并-嘧啶化合物和其用途
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
CN105189480A (zh) 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物
CN113348170A (zh) 联苯类衍生物抑制剂、其制备方法和应用
WO2022246459A1 (en) Combination therapy
HK40045721A (en) Heterocyclic compounds as kinase inhibitors
KR20250127267A (ko) 튜불린 중합 억제제
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK1192227B (en) Thiazolopyrimidine compounds
HK1201265B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045721

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210205

WD01 Invention patent application deemed withdrawn after publication